产品banner
location : Home >> Products >> Pharmaceutical process development

Product Center

Pharmaceutical process development

2020-06-01 15:40:17
Pharmaceutical process development
Detailed introduction:

◆ strictly abide by the customer's requirements for project time nodes and work quality

◆ strictly follow the SFDA drug process development guidelines

◆ provide "one-stop" process R & D services:

▶  Route design, development process optimization, amplification and handover, impurity research, quality standard research, registration and application assistance

◆ typical cases


Ticagrel:

Ticagrel is a new and selective small molecule anticoagulant. The drug can reversibly act on the purinoceptor 2 (P2) subtype P2Y12 on VSMC without metabolic activation, and has a significant inhibitory effect on the platelet aggregation caused by ADP. After oral administration, it has a rapid effect and can effectively improve the symptoms of patients with acute coronary heart disease.


 

 替卡格雷

 

 

Fonda anemone sodium:

Fondaparinux sodium (trade name: fondaparinux) is a highly selective inhibitor of thrombin cause Xa. It mainly exerts its effect through the special inhibition of antithrombin at Ⅲ on thrombin cause Xa. It is used for the prevention of deep vein thrombosis in adult patients after hip fracture surgery, hip and knee replacement and abdominal surgery. It has better drug safety than heparin and low molecular weight heparin.

磺达肝葵钠

 

Eichbrin:

Aizhibrin (trade name: halven) is a kind of microtubule inhibitor of non-zizane, developed by Eisai company of Japan. For the treatment of metastatic breast cancer patients, can extend the overall survival time of patients. In November 2010, FDA approved the listing, and in 2011, it was listed in Europe and Asia.

艾日布林

 

Palamivir:

New anti influenza drugs can effectively inhibit the replication and transmission of various influenza virus strains. They have the advantages of good tolerance and low toxicity, and are used to treat influenza A or B virus infection. At present, the drug has been listed in the United States and Japan.

帕拉米韦


Entecavir:

Entecavir (trade name: Baraclude) is a new first-line anti HBV drug developed by Bristol Myers Squibb Company. It can effectively inhibit the replication and transmission process of HBV-DNA. It has strong activity, good tolerance, small toxicity and other advantages. Its efficacy is better than lamivudine. It is used in the treatment of chronic hepatitis B patients.

恩替卡韦

 

依泽麦布:

依折麦布(商品名:Zetia)是由美国Schering-Plough和Merck公司合作研制的新型胆固醇吸收抑制剂,于2002年10月被FDA批准上市,商品名为艾泽庭(Zetia)。可作为饮食控制以外的辅助治疗,可单独或与HMG-CoA还原酶抑制剂(他汀类)联合应用于治疗原发性(杂合子家族性或非家族性)高胆固醇血症,可降低总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白B(ApoB)。

依折麦布

 

Huperzine A:

Huperzine A is a highly effective and selective inhibitor of acetylcholinesterase. As a natural product, huperzine A is mainly used to prevent and improve memory decline and Alzheimer's disease (AD). In addition, huperzine A can also protect neurons through anti oxidative stress and anti apoptosis pathway, repair a variety of experimental memory damage, and can be used for the treatment of learning disorders and memory loss in adolescents.

石杉碱甲


Previous:None
Next:None

Recently Viewed:

Related Products

Related News